← Back to Search

Probody Therapeutic

CX-2029 for Non-Hodgkin's Lymphoma

Phase 1 & 2
Waitlist Available
Research Sponsored by CytomX Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial will study the safety and effectiveness of an investigational drug, CX-2029, in treating subjects with head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, non-small cell lung cancer, or esophageal cancer.

Eligible Conditions
  • Non-Hodgkin's Lymphoma
  • Head and Neck Cancers
  • Esophageal Cancer
  • Solid Tumors
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The number of subjects experiencing a dose-limiting toxicity at various dose levels when given CX-2029 as a monotherapy
Secondary outcome measures
The percentage of subjects experiencing anti-cancer activity (ORR) at various dose levels when given CX-2029 as a monotherapy

Trial Design

3Treatment groups
Experimental Treatment
Group I: CX-2029 ExpansionExperimental Treatment1 Intervention
Evaluate antitumor activity of CX-2029
Group II: CX-2029 EscalationExperimental Treatment1 Intervention
Dose Escalation and Determination
Group III: CX-2029 BiomarkerExperimental Treatment1 Intervention
Characterization of CX-2029 in the tumor microenvironment in subjects with select tumor types
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CX-2029
2018
Completed Phase 2
~140

Find a Location

Who is running the clinical trial?

CytomX TherapeuticsLead Sponsor
7 Previous Clinical Trials
751 Total Patients Enrolled
Monika Vainorius, M.D.Study DirectorCytomX Therapeutics, Inc.
2 Previous Clinical Trials
225 Total Patients Enrolled
Alison Hannah, MDStudy DirectorCytomX Therapeutics, Inc.
2 Previous Clinical Trials
922 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
2018. "PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03543813.
~19 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top